OncoMatch/Clinical Trials/NCT06725121
Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant
Is NCT06725121 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Atezolizumab & Bevacizumab and Yttrium-90 (Y-90) for hepatocellular carcinoma (hcc).
Treatment: Atezolizumab & Bevacizumab · Yttrium-90 (Y-90) — The goal of this clinical trial is to learn if locoregional therapy and immunotherapy can be used together to help patients with hepatocellular carcinoma (HCC) and macrovascular invasion achieve liver transplantation. The main questions it aims to answer are: * How many patients will achieve transplant with this treatment strategy? * What will the 5-year survival and recurrence-free survival rates be for these patients? Participants will: * Undergo a biopsy of the tumor. * Receive locoregional therapy (SBRT or Y90) followed by immunotherapy (atezolizumab and bevacizumab) 2 to 6 weeks later, for a maximum of 9 months. * Be referred for a liver transplant and undergo the procedure if deemed eligible and safe. * If applicable, be followed for five years post-transplant with regular data collection.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Biomarker criteria
Required: AFP < 5000 ng/mL (< 5000 ng/mL)
Alpha Fetoprotein < 5000 ng/mL
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: any therapy for hepatocellular carcinoma other than liver resection or ablation
Exception: liver resection or ablation
Prior therapy for hepatocellular carcinoma other than liver resection or ablation
Lab requirements
Liver function
child pugh turcotte score a5 to b7
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify